Passa al contenuto
Merck
  • Comparing a combination of penicillin G and gentamicin to a combination of clindamycin and amikacin as prophylactic antibiotic regimens in prevention of clean contaminated wound infections in cancer surgery.

Comparing a combination of penicillin G and gentamicin to a combination of clindamycin and amikacin as prophylactic antibiotic regimens in prevention of clean contaminated wound infections in cancer surgery.

Journal of the Egyptian National Cancer Institute (2013-03-19)
Hadir A El-Mahallawy, Safaa Shawky Hassan, Hassan Ibrahim Khalifa, Mohamed M El-Sayed Safa, Medhat Mohamed Khafagy
ABSTRACT

Appropriate antibiotic selection and timing of administration for prophylaxis are crucial to reduce the likelihood of surgical site infection (SSI) after a clean contaminated cancer surgery. Our aim is to compare the use of two prophylactic antibiotic (PA) regimens as regards efficacy, timing, and cost. Two hundred patients with gastric, bladder, or colorectal cancer were randomized to receive preoperative PA, group A received penicillin G sodium and gentamicin and group B received clindamycin and amikacin intravenously. The demographic data of patients were collected, and they were observed for wound infections. Infected wounds occurred in 19 patients with a rate of 9.5%. Highest incidence of SSI was among bladder cancer patients (14.2%); p=0.044. The rate of SSI was 11% in group A, and 8% in group B, p=0.469. The cost of PA administered in group A was significantly less than that of group B (21.96±3.22LE versus 117.05±12.74LE, respectively; p<0.001). SSI tended to be higher among those who had longer time for antibiotic and incision (≥30min) than those who had shorter time interval (<30min), (13% vs. 6.5%, respectively). Both penicillin+gentamicin and clindamycin+amikacin are safe and effective for the prevention of SSI in clean contaminated operative procedures. In a resource limited hospital, a regimen including penicillin+gentamicin is a cost-effective alternative for the more expensive and broader coverage of clindamycin+amikacin. Timing of PA is effective in preventing SSIs when administered 30min before the start of surgery.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Penicillina G, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Penicillina G, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Clindamicina, lincosamide antibiotic
Sigma-Aldrich
Penicillina G, 96.0-102.0%
Sigma-Aldrich
Amikacin hydrate, aminoglycoside antibiotic
Sigma-Aldrich
Penicillina G, ~1650 U/mg
Sigma-Aldrich
Amikacin disulfate salt, potency: 674-786 μg per mg (as amikacin base)
Sigma-Aldrich
Penicillina G, 95.0 - 102.0%
Supelco
Clindamycin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Penicillina G
Clindamicina, European Pharmacopoeia (EP) Reference Standard
Supelco
Penicillina G, VETRANAL®, analytical standard
Amikacin, European Pharmacopoeia (EP) Reference Standard
Amikacin sulfate, European Pharmacopoeia (EP) Reference Standard
Amikacin for system suitability, European Pharmacopoeia (EP) Reference Standard